A U.S. federal judge this week upheld C.R. Bard’s (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard’s $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
"This has been a long and arduous journey for the parties in this litigation, but this should be the final curtain
of the saga," Circuit Court Judge Arthur Gajarsa of the U.S. Court of Appeals for the Federal Circuit wrote in the decision.
The decision was split 2 to 1 and Judge Gajarsa was rather candidly dismissive of the dissenting opinion:
"Contrary to the dissent, we are not free to ignore the long history of this case and these prior determinations," he wrote. "We cannot revisit the facts anew, nor meander through the record and select facts like our favorite jelly beans, nor characterize the facts as the Bard would in a Shakespearean tragedy."
The lawsuit has its roots in 1974 when Bard originally filed its patent for the grafts, devices used to bypass or reinforce blood vessels. The patent languished for 28 years while the companies debated who was the first to invent the device.
The lower court found had ruled that Gore was not the original inventor on the graft patent. The new ruling found that Gore was not a co-inventor, either.
- U.S. Judicial Panel orders 3 multidistrict litigations against transvaginal mesh-makers to be centralized in West Virginia
This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.
ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.
Take a look at our full agenda.
Use the code "TRACKS" to save 15% on the cost of registration.